TKT") and the consequent establishment of the Company's HGT business, together with the acquisitions of New River Pharmaceuticals in 2007 (which brought full rights to ADHD product VYVANSE), Jerini AG ("Jerini") in 2008 (which brought the HAE product FIRAZYR), EQUASYM
in 2009 (which facilitated Shire's immediate access to the European ADHD market) and Movetis NV ("Movetis") in 2010 (which brought EU rights to RESOLOR).
6 million); costs associated with the integration and acquisition of Jerini AG and EQUASYM
from UCB ($6.
Noven")) DERMAGRAFT (Human Fibroblast-Derived Dermal Substitute) ELAPRASE (idursulfase) EQUASYM
IR (methylphenidate hydrochloride) EQUASYM
XL (methylphenidate hydrochloride) FIRAZYR (icatibant) FOSRENOL (lanthanum carbonate) INTUNIV (guanfacine extended release) JUVISTA (trademark of Renovo Limited ("Renovo")) LIALDA (mesalamine) MEZAVANT (mesalazine) PENTASA (trademark of Ferring B.
b) Acquisitions and integration activities Costs associated with the acquisition of EQUASYM
6 million), costs associated with the integration and acquisition of Jerini and EQUASYM
for the treatment of ADHD in certain European countries;
and Jerini's Peptides business have been partially offset by cash outflows to acquire EQUASYM
, investment in property, plant and equipment at the HGT campus in Lexington and the dividend payment.
6 million), which comprise integration costs for Movetis and adjustments to the estimated contingent consideration for EQUASYM
0 million in the nine months to September 30, 2009 have been partially offset by investments in property, plant and equipment at the HGT campus in Lexington, the acquisition of EQUASYM
from UCB S.
We are committed to expanding our international business for both our Human Genetic Therapies and Specialty Pharmaceuticals products and have made progress during the quarter with the opening of a representative office in Japan and the acquisition of product rights for EQUASYM
, providing a European entry point for our Attention Deficit Hyperactivity Disorder portfolio.
TKT') and the consequent establishment of our HGT business, together with the acquisitions of Jerini AG ('Jerini') in 2008 (which brought the HAE product FIRAZYR), EQUASYM
in 2009 (which facilitated Shire's immediate access to the European ADHD market) and Movetis NV ('Movetis') in 2010 (which brought EU rights to RESOLOR and further developed our GI pipeline), provided Shire with the platforms to increase its presence in Europe and the RoW, thereby working towards diversifying the risk associated with reliance on one geographic market.
IR and XL will provide Shire with an entry to the European ADHD market upon completion of the transaction, which subject to customary completion conditions, is anticipated in Q2 2009.
XL is approved and marketed in 10 countries (outside the USA, Canada, and Barbados), and EQUASYM
IR is currently approved and marketed in four countries.
The acquisition of EQUASYM
IR and XL was accounted for as a business
UCB key products are Keppra(R) (antiepileptic), Xyzal(R) and Zyrtec(R) (antiallergics), Nootropil(R) (cerebral function regulator), Tussionex(R) (antitussive) and Metadate(R)CD / Equasym
XL(R) (attention-deficit/hyperactivity disorder).